Lentigen to Move Headquarters and Manufacturing to Gaithersburg

Lentigen to Move Headquarters and Manufacturing to Gaithersburg 

GAITHERSBURG, Md., Feb. 13 -- Lentigen Corporation today announced the company is moving its corporate headquarters and manufacturing facilities from the University of Maryland Baltimore County TechCenter to a new 26,000 square-foot facility in Gaithersburg.

Located along Maryland's I-270 technology corridor, the expanded facility will accommodate Lentigen's future growth needs as a leading developer and manufacturer of lentiviral vectors and proteins for a wide range of therapeutic and research applications. Two self-contained suites will allow simultaneous multi-product manufacture in compliance with FDA-regulated current good manufacturing practices and EMEA regulatory standards.

"We are very pleased to have found a facility that will meet our expansion requirements for both research-grade and clinical-grade operations," said Tim Ravenscroft, Lentigen's chief executive officer. "Located in the heart of Maryland's technology corridor, we will be well situated to attract talented individuals to our growing organization and to meet the increasing needs of our partners and customers."

About Lentigen Corporation

Lentigen Corporation is a privately owned biotechnology company focused on the development of lentiviral vector technology for a wide range of therapeutic, vaccine and research applications in biotechnology and medicine. Lentiviral vectors are the most efficient vehicles for the delivery of genes or gene silencing sequences stably into cells. Lentigen is a highly collaborative company, co-developing lentiviral vector-based products across a broad spectrum of bench to clinical applications. Partnerships include The National Institutes of Health, The University of Pennsylvania, ThermoFisher Scientific and The U.S. Army. For further information, visit http://www.lentigen.com/

Contact: Gregory Tiberend [email protected] Meghan Feeks [email protected] Richard Lewis Communications, Inc. 212-827-0020 SOURCE Lentigen Corporation

Suggested Articles

More than half of the participants met the primary endpoint, teeing Sanofi up to file for FDA approval of the complement C1s inhibitor.

Cellarity is combining artificial intelligence, a protein discovery platform and what it calls “network biology” in a new drug discovery approach.

Bluebird bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.